

PHARMACOLOGY

Quantitative Aspects of Drugs

OBJECTIVES:

- Determine quantitative aspects of drug receptor binding.
- Recognize concentration binding curves.
- Identify dose response curves and the therapeutic utility of these curves.
- Classify different types of antagonism





QUANTIFICATION OF DRUG ACTION



Concentration-Binding Curve:

The relationship between drug binding & drug concentration is expressed mathematically by the following equation:



(B_{max}): Total density of receptors in the tissue

(k_D) = Concentration of Drug required to occupy 50% of receptors at equilibrium



QUANTIFICATION OF DRUG ACTION

Concentration-Binding curves are used to determine:

- 1. The binding capacity $(B_{max}) \rightarrow$ total density of receptors in the tissues.
- 2. The affinity of Drug for receptor (The higher the affinity of Drug for receptor the lower is the K_D) i.e. inverse relation
- 3. Classification of receptors to receptor subtypes
- 4. K_D (Concentration of Drug required to occupy 50% of receptors at equilibrium)

Dose-Response Curves:

How does response vary with Concentration?



- lethal outcome



Dose-Response Curves

Features of Graded Dose-response Curve

- 1. Response is gradual
- 2. Gradual increase in response by increasing the dose (continuous response) .e.g. blood pressure, heart rate, blood glucose level, cholesterol,...
- 3. Curve is usually sigmoid in shape



*important note: As C ↑ → response ↑

Graded dose-response curves are used to determine:

- Max efficacy (E_{max}): is the maximal biological response produced by a drug. Also, E max means all of the receptor are occupied (B max)
- 2. Median effective concentration (EC50): is the concentration of the drug that gives 50% of (E max).
- **3. Potency :** the concentration of drug required to produce a specified response (Compare the relative potency and efficacy of drugs that produce the same effect).

Potency is inversely proportional to EC50.



Question: If we have three drugs A,B,C. EC50 for drug A = 10, EC50 for drug B = 50, EC50 for drug C = 100. Which one of them is more potent ?! Answer: drug A Why ? Because drug A produces the effect with small amount of concentration, and then will reduce the side effects.



More potent (A>B>C)

Quantal Dose-Response Curves:

Features of Quantal Dose-response Curve:

1. Relate drug concentration to % percentage of patients responding (all or none response).

2. The response may be: Therapeutic response, adverse effect or lethal effect.

Quantal dose-response curves are used to determine:

- 1. Median Effective Dose (ED50) : the dose of drug Required to exhibit a therapeutic effect in 50% of patients.
- 2. Median Toxic Dose (TD50) : the dose of drug required to exhibit a toxic effects in 50% of patients. (means the side effects)
- **3.** Median LETHAL Dose (LD50): the dose of drug required to exhibit death in 50% of patients.



Quantal Dose-Response Curves:

- 4. Therapeutic Index: It is a measure of safety profile.
 - Large value = Drug has a wide margin of safety. E.g. Diazepam
 - Small Value = Drug has a narrow margin of safety. E.g. Digoxin

Therapeutic Index = $\frac{TD50}{ED50}$



Antagonism

DEFINITION: It is the decrease or the complete abolishment of the effect of one drug in the presence of another.

Types of Antagonism:

- 1. Chemical Antagonism
- 2. Physiological Antagonism
- 3. Pharmacokinetics
- 4. Pharmacodynamics (Receptor Blockage)
 - Competitive: -Reversible -Irreversible
 - Non-Competitive



Antagonism

1. Chemical Antagonism:

- Simple chemical reaction & loss of activity
- No receptor.
- E.g. Dimercaprol reduces heavy metal toxicity (as in lead toxicity).

2. Physiological Antagonism:

- Two drugs act on different receptors to produce different physiological effects.
- E.g. Adrenaline & Histamine
- Adrenaline is used in anaphylactic shock to reverse action of histamine.

Adrenaline \rightarrow

Vasoconstriction ([↑] BP) & bronchodilation.

Histamine \rightarrow

vasodilatation (\downarrow BP) & bronchoconstriction.

3. Pharmacokinetic Antagonism:

- The antagonist effectively reduces the concentration of the active drug at the site of action.
- e.g. Phenobarbitone accelerates hepatic metabolism of warfarin



4. Pharmacodynamic Antagonism:

A) Competitive Reversible:

- Two drugs compete for the same receptor.
- The antagonist partially or completely prevents the pharmacological effect of agonist.
- Antagonist dissociate rapidly from receptor.
- Antagonism can be overcome by increasing the concentration of the agonist (Surmountable).
- Parallel shift of the curve to the right, without any change in slope or maximum
- E.g. acetylcholine and atropine.

B) Competitive Non-Reversible:

- Two drugs compete for the same receptor.
- Antagonist forms stable, permanent/near permenant chemical bond with receptor.
- The original response <u>can not be overcome</u> even by increasing the dose of the agonist (non-Surmountable).
- No parallel shift
- a decrease in slope and a reduced maximum are obtained.
- e.g. phenoxybenzamine and noradrenaline.





Reversible Parallel shift to the right, without any change in slope or maximum



Irreversible

No parallel shift But both a decrease in slope and a reduced maximum are obtained.

C) Non-Competitive:

- Antagonist block at some point the chain of events that stimulate the response of agonist.
- Agonist and Antagonist can be bound simultaneously.
- Antagonism cannot be overcome by increasing concentration of agonist (non-Surmountable).
- E.g. verapamil and noradrenaline.





THANK YOU FOR CHECKING OUR WORK THE PHARMACOLOGY TEAM

عبدالرحمن السياري خالد الزهراني عبدالله الجنيدل أحمد المصعبي مهند الزيد عبدالرحمن الشمري معاذ باعشن عبدالعزيز الشعلان

مريم سعيدان ساره الخليفه کیان کعکی نورة الطويل رنيم الدبيخي اسرار باطرفى منيرة الحسن ديمه الراجحي كوثر الموسى نوف العبدالكريم هديل الغرير لمي الزامل ويم العقيل سارا الحسين ر فان هاشم نوف الرشيد ديمة الفار س نورة العقبل ياسمين الفارسي

For any correction, suggestion or any useful information do not hesitate to contact us: Pharmacology.med435@gmail.com

435

ontact us: Pharmacology.med435@gr